Until Labs, Inc.

Based in the US, Until Labs, Inc. specializes in advanced cryopreservation technologies aimed at extending the viability of donated human organs, addressing critical challenges in organ transplantation. Until Labs is focused on transforming organ transplantation logistics through innovative cryopreservation methods. Founded in San Francisco, US, the company has attracted attention in the market, leading to a recent Series A round where it secured USD 58 mn from investors including Founders Fund, Lux Capital, and Field Ventures.

The funding round, completed on September 22, 2025, marks a significant milestone in their growth trajectory. Until specializes in advanced cryopreservation technologies aimed at significantly extending the viability of donated human organs. Their core offering transforms the traditional hours of organ viability into weeks or months, addressing the critical logistical challenges faced in organ transplantation. By leveraging innovative cryopreservation techniques, Until aims to ensure that no donated organs are lost due to logistical delays, thereby preventing patient mortality due to waiting times.

This technology serves a wide range of stakeholders within the medical community, including hospitals, transplant centers, and research institutions, primarily in North America and Europe, where the demand for organ transplants is highest. The company also lays the groundwork for future innovations in whole-body reversible cryopreservation, potentially benefiting patients with conditions that currently have no viable treatment options. Until's revenue model is centered on the provision of its cryopreservation services to healthcare institutions, primarily through direct partnerships with hospitals and transplant centers. Revenue is generated through service agreements, which may include usage fees for the application of their technology and potential subscription models for ongoing access to their cryopreservation solutions.

Specific pricing structures are tailored to the needs of each client, enabling a flexible approach that aligns with the varying capacities and requirements of healthcare providers. While the pricing details for individual services are proprietary, the strategic partnerships established with key healthcare organizations suggest a robust framework for revenue generation as the company scales its operations. The anticipated growth in the demand for organ transplantation services is expected to further enhance Until's revenue potential as it continues to innovate in this critical area of healthcare. Until Labs plans to utilize the USD 58 mn raised in its Series A funding round to support the growth of its multidisciplinary workforce.

The company is developing new cryopreservation products, aiming to enhance its offerings by expanding the range of services available to healthcare providers. Additionally, Until is targeting expansion into new markets, with a focus on increasing its presence in Europe and other high-demand regions by 2026, thereby aligning its growth strategy with rising organ transplantation needs.